The first oral drug for a common liver disease may be on the horizon
Non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease, refers to inflammation and damage of the liver caused by a build-up of fat. If NASH gets worse, it can cause scarring of the liver and cirrhosis. Weight loss is recommended in cases of obesity, but there are no medicines to treat it. Cyclophilins are a family of proteins that includes cyclophilin D. Inhibitors of cyclophilin D have been implicated as potential therapeutics but selective, oral agents have been elusive. CYPNASH has discovered a new family of small molecules that inhibit cyclophilins. With expertise in business, pharmaceuticals, and basic research, the team plans to streamline discovery and testing of a suitable NASH therapeutic.
Field of science
- /social sciences/economics and business
Call for proposal
See other projects for this call